Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Director departure
AMYLIN PHARMACEUTICALS INC (AMLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/13/2012 8-K Quarterly results
07/02/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Bristol-Myers Squibb Company, B&R Acquisition Company and Amylin Pharmaceuticals, Inc",
"Assumption Agreement, by and between Bristol-Myers Squibb Company and Amylin Pharmaceuticals, Inc"
06/29/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb's Acquisition of Amylin Pharmaceuticals"
06/18/2012 8-K Form 8-K - Current report
06/05/2012 8-K Other Events
05/16/2012 8-K Form 8-K - Current report
04/26/2012 8-K Quarterly results
Docs: "AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS"
03/09/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement",
"Opinion of Cooley LLP",
"AMYLIN PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK",
"AMYLIN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK"
03/06/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/09/2012 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
02/06/2012 8-K Quarterly results
Docs: "AMYLIN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS"
01/30/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Approves BYDUREON™ - The First and Only Once-Weekly Treatment for Type 2 Diabetes"
12/07/2011 8-K Form 8-K - Current report
11/08/2011 8-K Form 8-K - Current report
10/20/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "BYETTA ® Approved for Use with Insulin Glargine in the U.S."
10/19/2011 8-K Quarterly results
Docs: "AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS"
07/28/2011 8-K Form 8-K - Current report
07/08/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Exenatide tQT Study Showed No Prolongation of QT Interval"
06/09/2011 8-K Form 8-K - Current report
05/26/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "Order of the United States District Court for the Southern District of California"
05/25/2011 8-K Submission of Matters to a Vote of Security Holders
05/23/2011 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
05/17/2011 8-K Other Events, Financial Statements and Exhibits
Docs: "AMYLIN PHARMACEUTICALS FILES SUIT AGAINST ELI LILLY Complaint Alleges Anticompetitive Activity and Breach of Strategic Alliance Agreements"
04/18/2011 8-K Form 8-K - Current report
03/04/2011 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/03/2011 8-K Form 8-K - Current report
01/26/2011 8-K Form 8-K - Current report
12/03/2010 8-K Form 8-K - Current report
10/21/2010 8-K Form 8-K - Current report
07/21/2010 8-K Form 8-K - Current report
06/15/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "DURATION-4 Study Results: BYDUREON™ Efficacy and Tolerability Profile Extended to Monotherapy Treatment"
05/06/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "BYDUREON™ FDA REVIEW TIMELINE SET WITH PDUFA ACTION DATE OF"
04/30/2010 8-K Submission of Matters to a Vote of Security Holders
04/19/2010 8-K Quarterly results
Docs: "AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Non-GAAP Operating Loss Improves by 81% to $3.8 Million Compared to the First Quarter of 2009 BYDUREON Response to FDA Will Be Submitted This Week BYDUREON Marketing Authorization Application Submitted to the European Medicines Agency"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy